Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
***
SPONSOR: http://www.MarcinkoAssociates.com
***
According to the Organization for Economic Cooperation and Development’s November economic outlook report, global growth is on track to stay modest this year and into 2024. And, while gross domestic product growth has been stronger than anticipated in 2023 so far, it’s now “moderating on the back of tighter financial conditions, weak trade growth and lower business and consumer confidence,” the report’s authors noted. The OECD anticipates global GDP growth of 2.9% in 2023, and a dip to 2.7% in 2024. 2025 looks better, with predicted global growth of 3%.
***
The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the majority of whom are Black. The therapy, called Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is the first medicine to be approved in the United States.
CRISPR: https://medicalexecutivepost.com/2022/08/06/crispr-play-by-play-of-an-experiment/
Here is where the major benchmarks ended:
The S&P 500® Index (SPX) was up 0.41% at 4,604.46, up marginally for the week; the Dow Jones Industrial Average (DJI) was up 130 points (0.36%) at 36,247.87, up marginally for the week; the NASDAQ Composite® (COMP) was up 63.98 points (0.45%) at 14,403.97, up 0.7% for the week.The 10-year Treasury note yield (TNX) was up 10 basis points at 4.235%. The CBOE Volatility Index (VIX) was down 5.44% at 12.35.
CITE: https://www.r2library.com/Resource
COMMENTS APPRECIATED
Refer a Colleague: MarcinkoAdvisors@msn.com
Your referral Count: 0
Thank You
***
***
Share this:
Filed under: "Ask-an-Advisor", "Doctors Only", Breaking News, Drugs and Pharma, Experts Invited, Financial Planning, Investing, LifeStyle | Tagged: banks, CASGEVY, CBOE, CRISPR, energy, FDA, gold, inflation, Marcinko, markets, metals, NASDAQ, OECD, oil, real-estate, Russell Index 2000, RUT, S&P 500, sickle cell disease, SPX, stock markets, TNX, utilities, Vertex | Leave a comment »
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 